CTLA4 and autoimmune disease: The use of anti–PD-1, anti–PD-L1, or anti–CTLA-4 antibodies in patients with concomitant autoimmune disease is a procedure with a high risk of complications, therefore, it is not recommended to choose this type of treatment as adjuvant therapy.